Adverum Biotechnologies, Inc. - Common Stock (ADVM)
Frequently Asked Questions About Adverum Biotechnologies, Inc. - Common Stock (ADVM)
How can I invest in Adverum Biotechnologies?
Investors can buy shares of Adverum Biotechnologies, Inc. on the Nasdaq stock exchange under the ticker symbol ADVM. Interested investors should conduct thorough research, consider their financial strategies, and possibly consult with a financial advisor before making investment decisions.
How can I learn more about Adverum Biotechnologies?
To learn more about Adverum Biotechnologies, interested individuals can visit the company's official website, where they can find detailed information about its pipeline, clinical trials, financial news, and investor relations. Additionally, following the company on social media and subscribing to its press releases can provide ongoing updates.
How does Adverum approach regulatory approvals?
Adverum Biotechnologies follows a rigorous process to obtain regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). The company conducts comprehensive preclinical and clinical studies to establish safety and efficacy, aiming to comply with all regulatory guidelines to expedite the approval process for its innovative therapies.
How does Adverum Biotechnologies ensure patient safety?
Adverum Biotechnologies prioritizes patient safety by adhering to strict protocols during clinical trials, including comprehensive safety monitoring and rigorous data analysis. The company follows ethical guidelines and collaborates with regulatory bodies to ensure that its therapies are tested thoroughly before reaching patients.
How is Adverum Biotechnologies funded?
Adverum Biotechnologies is funded through a combination of equity financing, partnerships, and grants. The company has successfully raised capital through public offerings and private placements to support its ongoing research and clinical trials, while also looking for collaboration opportunities that can provide additional resources.
What are the current clinical trials conducted by Adverum?
Adverum is currently conducting clinical trials for ADVM-022 and other pipeline candidates in various stages of development. These studies are aimed at assessing safety, efficacy, and optimal dosing regimens for its gene therapies in patients with retinal diseases.
What are the future growth prospects for Adverum Biotechnologies?
The future growth prospects for Adverum Biotechnologies depend on the success of its ongoing clinical trials and the potential commercialization of its gene therapies. The company aims to expand its pipeline to address more diseases, while continuous advancements in gene therapy technologies may further enhance its market position and growth opportunities.
What competitive advantages does Adverum Biotechnologies have?
Adverum Biotechnologies possesses several competitive advantages, including its proprietary AAV technology platform, a robust pipeline of innovative therapies, and a strong team with deep expertise in gene therapy and ocular diseases. Additionally, its strategic partnerships enhance its research capabilities and market access.
What does Adverum Biotechnologies, Inc. do?
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company dedicated to developing innovative and transformative genetic medicines for ocular diseases and other serious health conditions. The company operates with a focus on leveraging its proprietary AAV (adeno-associated virus) technology platform to create therapies that can address the underlying genetic causes of diseases, aiming for long-lasting benefits for patients.
What is ADVM-022?
ADVM-022 is Adverum Biotechnologies’ lead product candidate, designed for the treatment of wet age-related macular degeneration (AMD). It utilizes the company’s innovative AAV technology to deliver a gene that encodes for anti-VEGF proteins, which play a crucial role in reducing abnormal blood vessel growth in the eye, thus addressing the underlying cause of vision loss.
What is the mission of Adverum Biotechnologies?
The mission of Adverum Biotechnologies is to transform the treatment of serious diseases through innovative gene therapies. By focusing on scientific excellence and patient-centered solutions, the company aims to provide lasting therapeutic effects that improve the quality of life for patients with genetic conditions.
What is the significance of Adverum's stock listing on Nasdaq?
Adverum Biotechnologies' listing on Nasdaq, under the ticker symbol ADVM, signals its status as a public company, providing investors with an opportunity to participate in the growth of the biotechnology sector. This listing also enhances the company’s visibility and credibility in the investment community, attracting institutional and retail investors interested in innovative therapeutic developments.
What is the significance of the AAV technology used by Adverum?
AAV, or adeno-associated virus, is a key technology in Adverum's gene therapy platform that allows for targeted delivery of genetic material into the patient's cells. This technology is significant because it can mediate long-term expression of therapeutic genes within tissues, potentially providing durable effects from a single treatment and significantly improving the management of chronic diseases.
What is the strategic vision of Adverum Biotechnologies?
Adverum Biotechnologies aims to be a leader in the development of innovative gene therapies that address the underlying causes of serious diseases. The company’s strategic vision includes advancing its proprietary AAV platform and expanding its pipeline, fostering collaborations, and maintaining a strong financial position to support ongoing research and commercialization efforts.
What partnerships or collaborations has Adverum Biotechnologies formed?
Adverum Biotechnologies has formed strategic partnerships and collaborations with various academic institutions, research organizations, and industry players to enhance its gene therapy research and development. These collaborations often focus on gene delivery technologies, clinical trial designs, and access to new markets or expertise.
What types of diseases is Adverum Biotechnologies focused on?
Adverum Biotechnologies primarily focuses on developing gene therapies for ocular diseases, including wet age-related macular degeneration (AMD), diabetic retinopathy, and other serious retinal conditions. The company is also exploring treatments for non-ocular diseases, expanding its gene therapy platforms to address other serious health conditions.
When was Adverum Biotechnologies founded?
Adverum Biotechnologies was founded in 2010. Since its inception, the company has been focused on groundbreaking genetic medicine, moving through various stages of development and innovation to advance its gene therapies for various diseases.
Where is Adverum Biotechnologies headquartered?
Adverum Biotechnologies is headquartered in Redwood City, California. This location places the company in the heart of Silicon Valley, an area known for its concentration of biotech and technology businesses, facilitating access to top talent, potential partnerships, and innovation.
Who are the key executives at Adverum Biotechnologies?
The key executives at Adverum Biotechnologies include a team of highly experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and gene therapy. This includes the CEO, who leads company strategy and operations, and other senior executives responsible for specific departments like research and development, finance, and regulatory affairs.
What is the current price of Adverum Biotechnologies, Inc. - Common Stock?
The current price of Adverum Biotechnologies, Inc. - Common Stock is 2.730
When was Adverum Biotechnologies, Inc. - Common Stock last traded?
The last trade of Adverum Biotechnologies, Inc. - Common Stock was at 4:00 pm EDT on April 21st, 2025
What is the market capitalization of Adverum Biotechnologies, Inc. - Common Stock?
The market capitalization of Adverum Biotechnologies, Inc. - Common Stock is 267.88M
How many shares of Adverum Biotechnologies, Inc. - Common Stock are outstanding?
Adverum Biotechnologies, Inc. - Common Stock has 98.13M shares outstanding.